Loading clinical trials...
Loading clinical trials...
A Phase I Trial to Evaluate the Safety and Immunogenicity of an Influenza Vaccination Strategy Including a H3N2 M2SR Prime Followed by a Seasonal Quadrivalent Inactivated Vaccine Boost in a Pediatric Population 9-17 Years Old
Conditions
Interventions
Influenza Virus Monovalent A/H3N2/Bris 10 M2SR Live Vaccine
Placebo
+1 more
Locations
1
United States
Saint Louis University - Center for Vaccine Development
St Louis, Missouri, United States
Start Date
August 15, 2018
Primary Completion Date
August 27, 2020
Completion Date
August 27, 2020
Last Updated
October 21, 2021
NCT01386424
NCT07169318
NCT07291635
NCT06599658
NCT06094010
NCT06753474
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions